Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Price, Quote, News and Overview

NASDAQ:IOBT - Nasdaq - US4497781090 - Common Stock - Currency: USD

0.9  -0.01 (-1.56%)

After market: 0.8999 0 (-0.01%)

IOBT Quote, Performance and Key Statistics

IO BIOTECH INC

NASDAQ:IOBT (3/5/2025, 8:04:23 PM)

After market: 0.8999 0 (-0.01%)

0.9

-0.01 (-1.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.85
52 Week Low0.66
Market Cap59.29M
Shares65.88M
Float65.66M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-27 2025-03-27/amc
IPO11-05 2021-11-05


IOBT short term performance overview.The bars show the price performance of IOBT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

IOBT long term performance overview.The bars show the price performance of IOBT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IOBT is 0.9 USD. In the past month the price decreased by -5.26%. In the past year, price decreased by -50.55%.

IO BIOTECH INC / IOBT Daily stock chart

IOBT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.9 373.82B
AMGN AMGEN INC 15.97 170.00B
GILD GILEAD SCIENCES INC 25.04 143.84B
VRTX VERTEX PHARMACEUTICALS INC 1695.31 126.30B
REGN REGENERON PHARMACEUTICALS 15.06 75.12B
ARGX ARGENX SE - ADR 247.66 38.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.15B
ONC BEIGENE LTD-ADR N/A 27.98B
BNTX BIONTECH SE-ADR N/A 27.51B
BIIB BIOGEN INC 8.73 20.95B
NTRA NATERA INC N/A 19.53B
GMAB GENMAB A/S -SP ADR 25.64 15.31B

About IOBT

Company Profile

IOBT logo image IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Company Info

IO BIOTECH INC

Ole Maaloes Veh 3

COPENHAGEN DK

Employees: 74

Company Website: https://www.iobiotech.com/

Investor Relations: https://www.iobiotech.com/about-us/#investors

Phone: 4570702980

IO BIOTECH INC / IOBT FAQ

What is the stock price of IO BIOTECH INC today?

The current stock price of IOBT is 0.9 USD. The price decreased by -1.56% in the last trading session.


What is the ticker symbol for IO BIOTECH INC stock?

The exchange symbol of IO BIOTECH INC is IOBT and it is listed on the Nasdaq exchange.


On which exchange is IOBT stock listed?

IOBT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IO BIOTECH INC stock?

12 analysts have analysed IOBT and the average price target is 9.18 USD. This implies a price increase of 920% is expected in the next year compared to the current price of 0.9. Check the IO BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IO BIOTECH INC worth?

IO BIOTECH INC (IOBT) has a market capitalization of 59.29M USD. This makes IOBT a Micro Cap stock.


How many employees does IO BIOTECH INC have?

IO BIOTECH INC (IOBT) currently has 74 employees.


What are the support and resistance levels for IO BIOTECH INC (IOBT) stock?

IO BIOTECH INC (IOBT) has a support level at 0.86 and a resistance level at 1.07. Check the full technical report for a detailed analysis of IOBT support and resistance levels.


Should I buy IO BIOTECH INC (IOBT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IO BIOTECH INC (IOBT) stock pay dividends?

IOBT does not pay a dividend.


When does IO BIOTECH INC (IOBT) report earnings?

IO BIOTECH INC (IOBT) will report earnings on 2025-03-27, after the market close.


What is the Price/Earnings (PE) ratio of IO BIOTECH INC (IOBT)?

IO BIOTECH INC (IOBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.37).


What is the Short Interest ratio of IO BIOTECH INC (IOBT) stock?

The outstanding short interest for IO BIOTECH INC (IOBT) is 0.04% of its float. Check the ownership tab for more information on the IOBT short interest.


IOBT Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to IOBT. When comparing the yearly performance of all stocks, IOBT is a bad performer in the overall market: 83.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IOBT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IOBT. While IOBT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IOBT Financial Highlights

Over the last trailing twelve months IOBT reported a non-GAAP Earnings per Share(EPS) of -1.37. The EPS increased by 44.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -100.44%
ROE -124.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%16.28%
Sales Q2Q%N/A
EPS 1Y (TTM)44.31%
Revenue 1Y (TTM)N/A

IOBT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to IOBT. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners67.38%
Ins Owners0.34%
Short Float %0.04%
Short Ratio0.15
Analysts
Analysts78.33
Price Target9.18 (920%)
EPS Next Y35.87%
Revenue Next YearN/A